Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMRANASDAQ:GNCAOTCMKTS:IMVIQOTCMKTS:MSLP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMRAComera Life Sciences$0.00$0.00$0.00▼$0.03$6K0.779,936 shsN/AGNCAGenocea Biosciences$0.00$0.00▼$0.00$6K1.6183,499 shsN/AIMVIQIMV$0.00$0.00▼$0.00$2K0.93,567 shsN/AMSLPMusclePharm$0.00$0.00▼$0.00$7K-0.0726,442 shsN/AMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMRAComera Life Sciences0.00%0.00%+100.00%0.00%-99.20%GNCAGenocea Biosciences0.00%0.00%0.00%0.00%+150.00%IMVIQIMV0.00%0.00%0.00%0.00%+100.00%MSLPMusclePharm0.00%0.00%0.00%0.00%-83.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMRAComera Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AGNCAGenocea BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AIMVIQIMVN/AN/AN/AN/AN/AN/AN/AN/AMSLPMusclePharmN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMRAComera Life Sciences 0.00N/AN/AN/AGNCAGenocea Biosciences 0.00N/AN/AN/AIMVIQIMV 0.00N/AN/AN/AMSLPMusclePharm 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMRAComera Life Sciences$1.00M0.01N/AN/AN/A∞GNCAGenocea Biosciences$1.91M0.00N/AN/A$0.47 per share0.00IMVIQIMV$330K0.00N/AN/A($0.69) per share0.00MSLPMusclePharm$50.04M0.00N/AN/A($0.94) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMRAComera Life Sciences-$18MN/A0.00∞N/AN/AN/AN/AN/AGNCAGenocea Biosciences-$33.20M-$0.61N/AN/AN/AN/A-182.88%-62.76%N/AIMVIQIMV-$37.99MN/A0.00N/AN/AN/AN/AN/AN/AMSLPMusclePharm-$12.87M-$0.58N/AN/AN/A-38.51%N/A-169.56%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMRAComera Life SciencesN/AN/AN/AN/AN/AGNCAGenocea BiosciencesN/AN/AN/AN/AN/AIMVIQIMVN/AN/AN/AN/AN/AMSLPMusclePharmN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMRAComera Life SciencesN/AN/AN/AGNCAGenocea Biosciences0.241.351.35IMVIQIMVN/AN/AN/AMSLPMusclePharmN/A0.250.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMRAComera Life SciencesN/AGNCAGenocea Biosciences0.64%IMVIQIMVN/AMSLPMusclePharm15.49%Insider OwnershipCompanyInsider OwnershipCMRAComera Life Sciences8.90%GNCAGenocea Biosciences1.61%IMVIQIMV0.33%MSLPMusclePharm60.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMRAComera Life Sciences230.74 million28.00 millionNot OptionableGNCAGenocea Biosciences7058.73 million57.79 millionNot OptionableIMVIQIMV10011.71 million11.67 millionNot OptionableMSLPMusclePharm2033.39 million13.12 millionNot OptionableIMVIQ, MSLP, CMRA, and GNCA HeadlinesRecent News About These CompaniesTry This Trick to Lose Weight and Gain Lean Muscle at the Same TimeOctober 28, 2024 | cnet.comEditorial PodcastsSeptember 23, 2024 | pharmexec.comPInterpreting the Mean Sea Level Pressure (MSLP) AnalysisSeptember 8, 2024 | bom.gov.auBThe No BS Guide to Building Lean MuscleAugust 15, 2024 | healthline.comHMuscle machine: How water controls the speed of muscle contractionJuly 31, 2024 | sciencedaily.comSStories about: muscle carMay 23, 2024 | autoevolution.comATop 10 FBB OnlyFans & Muscle Girl OnlyFans to Follow 2024April 20, 2024 | straight.comSTop 6 Best Lean Muscle Supplements in 2024March 26, 2024 | straight.comS🏋️♀️ The 10 Best Muscular OnlyFans Women of 2024 (OnlyFans Muscle Girls)March 20, 2024 | laweekly.comLBest Protein Powder For Muscle Gain, According To ExpertsFebruary 24, 2024 | forbes.comThe 5 best muscle rubs of 2024February 11, 2024 | businessinsider.com10 Best Protein Powders ReviewJanuary 3, 2024 | jpost.comJ7 Healthy Habits to Decrease the Risk of Breast CancerNovember 2, 2023 | msn.comFitLife Brands swoops in for bankrupt MusclePharm assetsOctober 2, 2023 | msn.comUS Bankruptcy Court Approves FitLife's $18.5M Acquisition Of MusclePharmSeptember 28, 2023 | msn.comFitLife Brands to Acquire Substantially All of the Assets of MusclePharm CorporationSeptember 27, 2023 | benzinga.comBest protein powders for muscle gain 2023: Promote hypertrophy by boosting post-workout protein consumptionSeptember 22, 2023 | expertreviews.co.ukEmuscle sensorAugust 18, 2023 | hackaday.comHBest Evidence Review: Muscle Cramps -- Painful, Common, and NeglectedAugust 3, 2023 | medscape.comMMuscle Fatigue vs. Mental Fatigue: How to Determine Which One Is Holding You BackJuly 23, 2023 | runnersworld.comRIMVIQ, MSLP, CMRA, and GNCA Company DescriptionsComera Life Sciences NASDAQ:CMRA$0.0002 0.00 (0.00%) As of 06/24/2025Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.Genocea Biosciences NASDAQ:GNCAGenocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.IMV OTCMKTS:IMVIQIMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.MusclePharm OTCMKTS:MSLPMusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides Palantir Stock Hits ATH, But Can the Rally Hold Without Volume? Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
